Zymeworks Appoints Schayowitz EVP R&D and Platshon EVP Business Officer
Zymeworks named Dr. Adam Schayowitz EVP of R&D and Scott Platshon EVP Chief Business Officer on April 9, 2026, promoting both from interim roles and reporting to CEO Kenneth Galbraith. Schayowitz will steer oncology program advancements into clinical trials while Platshon oversees cash flow from Ziihera® and pasritamig assets.
1. Executive Appointments
On April 9, 2026, Zymeworks named Dr. Adam Schayowitz Executive Vice President and Head of Research & Development and Scott Platshon Executive Vice President and Chief Business Officer, elevating both from interim roles to report directly to CEO Kenneth Galbraith. Both executives join from EcoR1 Capital, a major shareholder, strengthening investor alignment.
2. Roles and Responsibilities
Schayowitz will lead the company’s oncology and R&D teams, focusing on advancing programs such as ZW251 into clinical stages, while Platshon will drive the asset aggregation strategy, overseeing revenue streams from Ziihera® (zanidatamab-hrii) and pasritamig, now entering Phase 3 studies by Johnson & Johnson.
3. Strategic Significance
These leadership appointments align with Zymeworks’ execution-focused strategy, leveraging recent milestones like Phase 1 initiation of ZW251 and positive Phase 3 HERIZON-GEA-01 data, to optimize cash flows, expand licensed assets and accelerate development of novel biotherapeutics.